md-medicaldata

Authors

 

Miljana Poparić¹, Nevena Sečen^1,2, Jovan Matijašević^1,3, Jovan Baljak¹, Nikola Gardić<sup>1,4

1</sup>Univerzitet u Novom Sadu, Medicinski fakultet, Hajduk Veljkova 1, Novi Sad, Srbija
²Institut za plućne bolesti Vojvodine, Klinika za pulmološku onkologiju, Sremska Kamenica, Srbija
³Institut za plućne bolesti Vojvodine, Klinika za urgentnu pulmologiju, Sremska Kamenica, Srbija
⁴Institut za plućne bolesti Vojvodine, Služba za patološko-anatomsku i molekularnu dijagnostiku, Sremska Kamenica, Srbija

 

UDK: 616.11-003.2
616.234-006.6-06

The paper was received / Rad primljen: 22.02.2024

Accepted / Rad prihvaćen: 20.03.2024.

 

Correspondence to:

Nikola Gardić
Institut za plućne bolesti Vojvodine,
Sremska Kamenica, Srbija
e-mail: nikola.gardic@institut.rs

 

 

Sažetak

 

 

Uvod: Karcinom bronha je druga po incidenci i prva po moratlitetu maligna neoplazma. Zahvatanje tumora perikarda i srca može dovesti do nastanka perikardnog izliva čija je najozbiljnija klinička manifestacija preteća tamponada srca, koja bez pravovremenog lečenja može dovesti do komplikacija opasnih po život. Cilj rada: Cilj ovog istraživanja je analiza učestalosti perikardnih izliva u zavisnosti od patohistološkog tipa karcinoma bronha, kod bolesnika kod kojih je primenjen različit vid lečenja karcinoma bronha. Materijal i metode: Retrospektivno, opservaciono-deskriptivno istraživanje je sprovedenou Institutu za plućne bolesti Vojvodine u Sremskoj Kamenici. Dobijeni podaci su prikupljeni iz medicinske dokumentacije informacionog sistema Instituta, JZIS. U studiju je uključeno 70 pacijenta sa dijagnozom karcinoma bronha kod kojih je prisustvo perikardnog izliva potvrđeno transtorakalnim ehokardiografskim pregledom. Rezultati: Bekova trijada ukazuje na tamponadu srca, koja obuhvata: hipotenziju koja je bila prisutna kod 19 (27,1%) pacijenata, sistemski venski zastoj koji je bio potvrđen kod 22 (31,4%) pacijenta, nečujni srčani tonovi koji su prilikom auskultacije potvrđeni kod 27 (38,6%) pacijenta. U zavisnosti od patohistološkog tipa karcinoma, perikardni izliv se najčešće je registrovan kod adenokarcinoma 50 (72%) i u podjednakoj učestalosti kod skvamoznog 10 (14%) i mikrocelularnog karcinoma 10 (14%), ali statistički značajna razlika između ova tri tipa karcinoma u količini perikardnog izliva nije dobijena (p> 0,05). Zaključak: Naši podaci pomažu kliničarima da identifikuju pacijente kod kojih postoji mogućnost nastanka peikardnog izliva i pruže im odgovarajući vid lečenja, kako bi se sprečio fatalan ishod bolesti.

 

Ključne reči:

karcinom pluća; perikardni izliv; tamponada srcaAbstract

 

 

 

Abstract

 

Introduction: Bronchial carcinoma is the second most common malignant neoplasm and the leading cause of mortality.Tumor involvement of the pericardium and heart can lead to pericardial effusion, the most serious clinical manifestation of which is cardiac tamponade. Without timely treatment, this condition can lead to life-threatening complications.The aim: The aim of this research is to analyze the frequency of pericardial effusions based on the histopathological type of carcinoma among patients who have undergone various treatments for the condition. Material and methods: A retrospective, observational-descriptive study was conducted at the Institute for Pulmonary Diseases of Vojvodina in Sremska Kamenica. Data were obtained from the medical documentation of the Institute's information system, JZIS. The study comprised 70 patients diagnosed with bronchial cancer, all of whom underwent transthoracic echocardiographic examination confirming the presence of pericardial effusion. Results: Beck's triad, indicative of cardiac tamponade, includes hypotension, observed in 19 (27.1%) patients; systemic venous stasis, confirmed in 22 (31.4%) patients; and silent heart sounds, detected during auscultation in 27 (38.6%) patients.Pericardial effusion was most frequently observed in adenocarcinoma (50 cases, 72%), followed by squamous (10 cases, 14%) and microcellular carcinoma (10 cases, 14%). However, no statistically significant difference was observed in the incidence of pericardial effusion among these three types of cancer (p > 0.05). Conclusion: Our data help clinicians identify patients at risk of developing pericardial effusion and provide appropriate treatment to prevent fatal outcomes.

 

Key words:

lung cancer; pericardial effusion; pericardial tamponade

 

 

 

 

References:

1. Cavic M, Kovacevic T, Zaric B, Stojiljkovic D, Korda NJ, Rancic M, Jankovic R, Radosavljevic D, Stojanovic G, Spasic J. Lung Cancer in Serbia. J Thorac Oncol. 2022 Jul;17(7):867-872.
2. Bokan D, Zaric B, Kovacevic T, Malbasa JD, Andrijevic I. 136P Lung cancer epidemiology and survival outcomes in Vojvodina, Serbia. Annals of Oncology. 2022 Apr 1;33:S94.
3. Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chem Biol Interact. 2019;309:108720.
4. Milašinović G, urednik. Nacionalni vodič dobre kliničke prakse za dijagnostikovanje i lečenje karcinoma pluća, Beograd: Agencija za akreditaciju zdravstvenih ustanova Srbije; 2012. 151-6.
5. Hu ZG, Hu K, Li WX, Zeng FJ. Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion. PLoS One. 2019;14(5):e0217007.
6. Lazarević A. Ehokardiografski vođena perikardiocenteza. Scri Med.2004;35(1);43-9.
7. Tohidinezhad F, Pennetta F, Van Loon J, Dekker A, de Ruysscher D, Traverso A. Prediction models for treatment-induced cardiac toxicity in patients with non-small-cell lung cancer: A systematic review and meta-analysis. Clin Transl Radiat Oncol. 2022;33:134-44.
8. Chang LK, Kuo YW, Wu SG, Chung KP, Shih JY. Recurrence of pericardial effusion after different procedure modalities in patients with non-small-cell lung cancer. ESMO Open. 2022;7(1):100354.
9. Yonemori K, Kunitoh H, Tsuta K, Tamura T, Arai Y, Shimada Y et  al. Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. Med Oncol. 2007;24(4):425-30.
10. Chahine J, Shekhar S, Mahalwar G, Imazio M, Collier P, Klein A. Pericardial Involvement in Cancer. Am J Cardiol. 2021;145:151-9.
11. Vemireddy LP, Jain N, Aqeel A, Jeelani HM, Shayuk M. Lung Adenocarcinoma Presenting as Malignant Pericardial Effusion/Tamponade. Cureus. 2021;13(3):e13762.
12. Kaira K, Takise A, Kobayashi G, Utsugi M, Horie T, Mori T et al. Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. Jpn J Clin Oncol. 2005;35(2):57-60.
13. Wang PC, Yang KY, Chao JY, Liu JM, Perng RP, Yen SH. Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest. 2000;118(3):744-9.
14. Cella L, Monti S, Xu T, Liuzzi R, Stanzione A, Durante M et al. Probing thoracic dose patterns associated to pericardial effusion and mortality in patients treated with photons and protons for locally advanced non-small-cell lung cancer. Radiother Oncol. 2021;160:148-58.
    

PDF: 04-Poparić M. et al MD-Medical Data 2024;16(1) 031-035.pdf